Rein Therapeutics, Inc.RNTXEarnings & Financial Report
Nasdaq
RNTX Q3 2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-5.5M
Net Profit
$-5.6M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.21
Rein Therapeutics, Inc. Q3 2025 Financial Summary
Rein Therapeutics, Inc. reported revenue of $0 for Q3 2025, with a net profit of $-5.6M (N/A margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-5.6M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 2025 |
Rein Therapeutics, Inc. Annual Revenue by Year
Rein Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $0).
| Year | Annual Revenue |
|---|---|
| 2024 | $0 |
| 2023 | $0 |
| 2022 | $0 |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $106.0M | $99.2M | $109.4M | $104.2M | $62.2M | $57.6M | $57.5M | $53.7M |
| Liabilities | $7.7M | $7.9M | $8.4M | $9.0M | $7.8M | $7.7M | $9.5M | $7.5M |
| Equity | $6.9M | $91.3M | $101.0M | $95.2M | $54.4M | $49.9M | $48.0M | $46.2M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-10.4M | $-5.3M | $-8.4M | $-3.8M | $-4.8M | $-6.2M | $-6.4M | $-3.5M |